التفاصيل البيبلوغرافية
| العنوان: |
Recombinant Activated Factor VII in Aortic Surgery for Patients Under Hypothermic Circulatory Arrest. |
| المؤلفون: |
Ise, Hayato, Ushioda, Ryohei, Kanda, Hirotsugu, Kimura, Fumiaki, Saijo, Yasuaki, Akhyari, Payam, Lichtenberg, Artur, Kamiya, Hiroyuki |
| المصدر: |
Therapeutics & Clinical Risk Management; Apr2022, Vol. 18, p337-348, 12p |
| مصطلحات موضوعية: |
INTERNATIONAL normalized ratio, PARTIAL thromboplastin time, AORTA, BLOOD coagulation factors, PROPENSITY score matching |
| مستخلص: |
Purpose: We aimed to identify the risk factors of critical bleeding and investigate the safety of recombinant activated factor VII (rFVIIa) in aortic surgery under hypothermic circulatory arrest (HCA). Patients and Methods: The present single-center retrospective study compared the baseline characteristics of 144 patients who underwent aortic surgery under HCA at our institute. Among the total cohort of 144 patients, 42 received rFVIIa (rFVIIa group), while the remaining 102 patients did not (non-rFVIIa group). Perioperative bleeding and transfusions, postoperative 30-day mortality, and adverse events (AEs) were analyzed in 29 propensity score-matched pairs. Results: Before surgery, the rFVIIa group demonstrated a greater number of shocks (p=0.019), higher JapanSCORE II mortality rate (p=0.033), low platelet count (p=0.015) and fibrinogen (p< 0.001) level, prolonged activated partial thromboplastin time (aPTT) (p=0.005) and prothrombin time international normalized ratio (PT-INR) (p=0.006), and longer aortic cross clamp time (p=0.049). Postoperative bleeding, transfusion, 30-day mortality, and AEs were comparable between the groups both in the entire-unmatched cohort and propensity score matching cohort. Conclusion: Preoperative shock, higher JapanSCORE II mortality rates, low platelet and fibrinogen levels, prolonged aPTT and PT-INR, and longer aortic clamping time might be risk factors for excessive bleeding and indicate the need for rFVIIa treatment. The present study suggests that rFVIIa can be safely used to address critical and continuous bleeding in spite of adequate transfusion and supplementation of other coagulation factors in aortic surgery under HCA, without an increase in 30-day mortality and AEs. [ABSTRACT FROM AUTHOR] |
|
Copyright of Therapeutics & Clinical Risk Management is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder